Menlo Therapeutics has reported negative top-line results from the Phase ll MTI-110 (TUSSIX) clinical trial that evaluated serlopitant for the treatment of refractory chronic cough.

The trial, which enrolled 185 patients, failed to meet its primary and key secondary endpoints of providing improved benefits by serlopitant over placebo.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Results demonstrated that in the primary endpoint review of change from baseline in 24-hour cough frequency after 12 weeks of treatment, the serlopitant group witnessed 31% less reduction than the placebo group.

In a key secondary evaluation of response rates, it was found that 54% of patients receiving placebo and 44% of patients treated with serlopitant experienced a 30% or greater reduction in 24-hour cough frequency at week 12 compared to baseline.

However, Serlopitant was reported to be well-tolerated in the trial.

Adverse events associated with treatment occurred at comparable rates in both the serlopitant and placebo groups.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Based upon the results of this trial, we do not anticipate further development of serlopitant for the treatment of refractory chronic cough.”

Menlo Therapeutics CEO Steve Basta said: “Based upon the results of this trial, we do not anticipate further development of serlopitant for the treatment of refractory chronic cough.

“We are continuing the clinical development of serlopitant for pruritus associated with various conditions given the two successful Phase ll clinical trials in which serlopitant demonstrated a reduction in chronic pruritus and pruritus associated with prurigo nodularis.”

In addition, Menlo is currently enrolling patients in two Phase lll clinical trials to investigate serlopitant as a treatment for pruritus associated with prurigo nodularis.

The results from each trial are expected to be available in the first half of 2020.

Serlopitant is an investigational, once-daily neurokinin 1 (NK1) receptor antagonist that aims to treat pruritus, or itch, associated with several conditions.